Self-limiting severe neutropenia in a patient with COVID-19

Ram Singh , Brajesh Kumar Ratre, Prashant Sirohiya , Sushma Bhatnagar

SUMMARY

Neutropenia is a rare haematological complication of COVID-19 infection in immunocompetent patients. There is sparse literature on neutropenia in patients with COVID-19, except a few case reports. We encountered a similar case in an intensive care unit that developed severe neutropenia on day 24 of illness. Neutropenia resolved spontaneously on 4th day of its appearance. The patient was isolated and kept under close observation, antibiotics were upgraded and strict asepsis was maintained. Thus, we observed in a patient with no comorbidities and uncomplicated neutropenia that strict measures to prevent infection may suffice and the undue risk of hematopoietic therapy can be avoided. An expert opinion should always be sought in such cases as the presence of complications may require an aggressive approach.

BACKGROUND

Infection with SARS-CoV-2 or COVID-19 has been linked with a range of haematological manifestations. Lymphocytopenia is the most commonly reported among hematopoietic abnormalities.1 Severe neutropenia is a rarely observed phenomenon in patients infected with COVID-19 with only a few case reports.2 3 The available literature is insufficient about its management in such a scenario. In our patient, the neutropenia was self-limited and resolved on its own within 3 days of its onset with the following conservative measures only. As the safety of administration of hematopoietic agents such as granulocyte-colony stimulating factor (G-CSF) in patients with COVID-19 is still not established, its prescription in uncomplicated neutropenia could be avoided. Furthermore, an expert opinion from a haematologist should always be sought while managing such cases.

CASE PRESENTATION

A 33-year-old man with no known comorbidities and a confirmed severe SARS-CoV-2 was admitted with the severe disease with impending respiratory failure in the intensive care unit (ICU); his condition improved subsequently and mode of oxygen support gradually titrated from high-flow nasal cannula, non-rebreathing mask and face mask to nasal cannula. The patient had improved clinically and was about to be shifted to the ward. The transfer to the ward was held due to incidental findings of severe neutropenia (an absolute neutrophil count (ANC) of 119/µL) on the 24th day of illness (ie, day 14th of the admission) on a routine investigation. It was a sudden drop in ANC from 4500/µL in the last 48 hours. The patient had received antibiotic ceftriaxone 1 g 12 hourly for 12 days, dexamethasone 8 mg two times per day and dalteparin 5000 U once daily. The patient had also received an intravenous injection of remdesivir 200 mg on day 1 of admission followed by 100 mg for the next 4 days (at the day of illness 11th–15th). The lymphopenia was present since early in the disease. Total leucocyte count (TLC) was 0.970 x10^9/L, ANC 119/µL (12.3% of TLC) and lymphocytes 261 (27% of TLC). No decrease in absolute count of other granulocytes, red blood cells or platelets was observed. Monocyte count was 299/µL (30.9% of TLC), basophil count was 27/µL (2.8% of TLC), eosinophil count was 805/µL (8.3% of TLC) and platelet count was 253 x10^9/L. A haematologist was consulted for any further workup to rule out the possibility of any concurrent haematological disorder. A multidisciplinary team of ICU decided to hold any hematopoietic therapy until a full evaluation of the patient while keeping the patient under close observation for any infectious complications. ANCs showed a slight increase in the next day to 195/µL. The patient was afebrile and vital signs were stable. Antibiotics de-escalated and then stopped as none of the specimens revealed positivity on culture sensitivity. The patient was asymptomatic and discharged to home on the 34th day of illness.

INVESTIGATIONS

In blood sample from same day when neutropenia was detected, the levels of inflammatory markers were interleukin-6 (IL-6) 1.2 pg/mL (normal range 0–4.4 pg/mL), C reactive protein 0.1 mg/mL (normal range 0–0.5 mg/dL), procalcitonin 0.06 ng/mL (normal range 0–0.1 ng/mL), lactate dehydrogenase 242 U/L, ferritin 476 ng/mL and D-dimer 251 ng/mL. Liver, kidney and hematocrit function tests were normal. Trend of ANC, a relationship between percentage of lymphocyte and neutrophil, and IL-6 levels during hospitalisation in our patient is shown in figure 1.

The blood, urine and sputum samples were taken for culture sensitivity and a peripheral smear for malaria was also negative. A repeat nasopharyngeal swab for reverse transcriptase-PCR for SARS-CoV-2 tested positive.
To rule out the viral, protozoal, autoimmune and nutritional causes for neutropenia following tests were done. Viral serology for HIV, hepatitis B surface antigen, hepatitis C virus, Epstein-Barr virus, parvovirus B19 and toxoplasma was negative or inconclusive. A peripheral smear was negative for malaria parasites. The autoimmune screening was negative for antinuclear antibodies, antineutrophil cytoplasmic antibodies, anti-dsDNA, β2 glycoprotein IgG and IgM, direct antiglobulin test and antithyroid antibodies. Serum Ig levels and protein electrophoresis revealed a normal study. Serum vitamin B12, folate and iron parameters were also within normal limits.

No evidence of any lymph node enlargement or organomegaly was observed in ultrasonography of the abdomen and pelvis and whole-body CT scan.

DIFFERENTIAL DIAGNOSIS

The possibility of iatrogenic neutropenia was ruled out as none of the drugs in the regimen including remdesivir or ceftriaxone were strongly associated with isolated neutropenia with such a short duration of treatment. Viral, protozoal, autoimmune and nutritional causes for neutropenia were also ruled out with appropriate testing. No history of malignancy in the family or any clinical or diagnostic features suggestive of it were found on evaluation.

TREATMENT

Antibiotics and antifungals were upgraded according to the sensitivity pattern of local flora of ICU to meropenem and teicoplanin and voriconazole. The patient was shifted to an isolated cabin to prevent cross-infection and was kept under close observation and the ICU staff were instructed to maintain strict asepsis.

OUTCOME AND FOLLOW-UP

The patient remained symptom free throughout the neutropenia phase, gradually oxygen therapy discontinued, antibiotics were de-escalated and then were stopped as none of the specimens revealed positivity on culture sensitivity. The patient was asymptomatic and was discharged home on the 34th day of illness. The patient was followed up for 2 weeks over a telephonic conversation, was symptom free, healthy and had resumed his job.

DISCUSSION

Among haematological abnormalities in patients with COVID-19, the incidence of lymphocytopenia ranged from 39% to 83%, with thrombocytopenia 5%–36% and leucopenia 17%–33% across various previous studies. The previous studies do not mention neutropenia as a manifestation of COVID-19 infection. There are only a few previous case reports on neutropenia in otherwise immunocompetent adult patients and an infant. The neutropenia in patients with COVID-19 with haematological malignancy or solid tumour has also been reported. Drug-induced neutropenia could also be the reason as described in the previous two reports. We had also screened our patients for any drug-induced cytopenia but did not find any offending agent. The patient was further evaluated for neutropenia as described in the previous studies. After a thorough clinical history and physical examination, we evaluated the patient for any other concurrent viral or protozoan infections known to cause cytopenia. An autoimmune screening, peripheral blood smear and blood level of folate, vitamin B12 and iron were also done. No significant findings could be found on screening for any concurrent viral or protozoan infections, autoimmune screening, peripheral blood smear and blood level of folate, vitamin B12, and imaging studies. Our multidisciplinary team of ICU decided to hold any further invasive testing including bone marrow examination and administration of any hematopoietic agent as G-CSF and kept the patient under close watch. A similar approach was observed in one of the previous case reports where in an otherwise healthy patient with delayed neutropenia after recovery from COVID-19, non-invasive laboratory tests to rule out the most likely causes were performed and a watchful-waiting approach was followed rather than performing invasive investigations such as bone marrow biopsy or administering G-CSF but we differ in this aspect with respect to other previous reports, as the patient in our case was more stable and asymptomatic and also did not have any family history of malignancy. The administration of G-CSF in COVID-19 could be detrimental and may cause early development of acute respiratory distress syndrome and worsening of the condition of the patient by modulating the immune system. On day 3, ANC was>1200/µL, other routine laboratory investigations were also normal and the patient also improved clinically from COVID-19. Thus, it is learnt from this experience and available literature that an early or delayed severe neutropenia could be found during severe COVID-19 infection and could be a result...
Neutropenia is a rare but prevalent haematological complication in patients with COVID-19. The incidence of neutropenia in COVID-19 could be underestimated as many cases might go unnoticed due to the self-limiting nature of neutropenia. All cases might not require painful and invasive investigations such as bone marrow to rule out other relevant causes. All cases with neutropenia might not require haematopoietic therapy and the decision to administer must be balanced against benefit and harm. Specialist haematologist consultation or opinion is a must in such cases.

Learning points

- Neutropenia is a rare but prevalent haematological complication in patients with COVID-19.
- The incidence of neutropenia in COVID-19 could be underestimated as many cases might go unnoticed due to the self-limiting nature of neutropenia.
- All cases might not require painful and invasive investigations such as bone marrow to rule out other relevant causes.
- All cases with neutropenia might not require haematopoietic therapy and the decision to administer must be balanced against benefit and harm.
- Specialist haematologist consultation or opinion is a must in such cases.

Twitter Prashant Sirohiya @sirohiyap
Contributors RS: Planning, manuscript writing, reporting the work and case management and also acts as the guarantor. BKR: Editing, final approval of manuscript and case management. PS: Final approval and case management. SB: Critical review and Final approval
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Consent obtained directly from patient(s).
Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

ORCID IDs
Ram Singh http://orcid.org/0000-0002-8542-873X
Prashant Sirohiya http://orcid.org/0000-0002-8418-4892

REFERENCES
1 Erdinc B, Sahni S, Gottlieb V. Hematological manifestations and complications of COVID-19. Adv Clin Exp Med 2021;30:101–7.
2 Devi YM, Sehrawat A, Panda PK, et al. Febrile neutropenia due to COVID-19 in an immunocompetent patient. BMJ Case Rep 2021;14:e242683.
3 López-Pereira P, Iturrate I, de La Cámara R, et al. Can COVID-19 cause severe neutropenia? Clin Case Rep 2020;8:3348–50.
4 Mank VMF, Mank J, Ogle J, et al. Delayed, transient and self-resolving neutropenia following COVID-19 pneumonia. BMJ Case Rep 2021;14:e242596.
5 Boulama B, Prieret C, Khelfaoui F, et al. Post-COVID-19 severe neutropenia. Pediatr Blood Cancer 2021;68:e28866.
6 Spencer HC, Wurzburger R. COVID-19 presenting as neutropenic fever. Ann Hematol 2020;99:1939–40.
7 Hernandez JM, Quares R, Lakshmi S, et al. Pancytopenia and profound neutropenia as a sequela of severe SARS-CoV-2 infection (COVID-19) with concern for bone marrow involvement. Open Forum Infect Dis 2021;8:ofab017.
8 Figuero-Pérez L, Olivares-Hernández A, Escala-Cornejo RA, et al. Management of febrile neutropenia associated with SARS-CoV-2 infection in a patient with cancer. JCO Oncol Pract 2020;16:348–9.
9 Meyre PB, Radosavac M, Baumann L, et al. COVID-19 in a patient with accidental drug-induced neutropenia. Eur J Case Rep Intern Med 2020;7:001848.
10 Gee S, Taylor D. The effect of COVID-19 on absolute neutrophil counts in patients taking doxazosine. Ther Adv Psychopharmacol 2020;10:204512532094093.
11 Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Semin Hematol 2013;50:198–206.
12 Tralongo AC, Extermann M. Older patients with cancer and febrile neutropenia in the COVID-19 era: a new concern. J Geriatr Oncol 2020;11:1329–30.
13 Selim S. Leukocyte count in COVID-19: an important consideration. Egypt J Bronchol 2020;14.